Template:Terazosin: Difference between revisions
Jump to navigation
Jump to search
(Created page with "{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; ! style="padding: 0 5px; font-size: 100%; background:#F8F8...") |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Terazosin|{{fontcolor|#6C7B8B|Terazosin}}]]''''' | ! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Terazosin|{{fontcolor|#6C7B8B|Terazosin}}]]''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Terazosin<sup>®</sup>, Hytrin<sup>®</sup> FDA Package Insert | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Terazosin indications and usage|Indications and Usage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Terazosin indications and usage|Indications and Usage]] | ||
| Line 8: | Line 8: | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Terazosin dosage and administration|Dosage and Administration]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Terazosin dosage and administration|Dosage and Administration]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Terazosin | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Terazosin contraindications|Contraindications]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Terazosin | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Terazosin warnings |Warnings]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Terazosin | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Terazosin precautions|Precautions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Terazosin adverse reactions|Adverse Reactions]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Terazosin adverse reactions|Adverse Reactions]] | ||
| Line 27: | Line 27: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Terazosin nonclinical toxicology|Nonclinical Toxicology]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Terazosin nonclinical toxicology|Nonclinical Toxicology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Terazosin how supplied storage and handling|How Supplied/Storage and Handling]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Terazosin how supplied storage and handling|How Supplied/Storage and Handling]] | ||
Latest revision as of 19:45, 12 March 2014
| Terazosin |
|---|
| Terazosin®, Hytrin® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Terazosin |
| ClinicalTrials.gov |